If you receive financial assistance from Vertex GPS™ for a modulator therapy (e.g., Trikafta®, Symdeko®, Orkambi®, or Kalydeco®), you may be impacted by changes Vertex has made to its copay assistance program. The following tips can help you understand how you may be impacted and what next steps may be available to you.
Site Search
The excitement we experienced anticipating our daughter, Tegan, starting Trikafta® gave way to sadness and confusion as she experienced emotional side effects.
On the brink of being listed for lung transplant, I started Trikafta®, which has helped stabilize my health and helped me avoid it for now, but a transplant could be in my future.
In a letter to California's Assembly Committee on Health, the Cystic Fibrosis Foundation expressed its support for AB 2180, which, if passed, would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements, as well as require covered benefits to be considered essential health benefits.
The Cystic Fibrosis Foundation joined the Partnership for Protecting Coverage in a letter to Alabama legislators opposing SB 232, a bill that could ultimately authorizing a nonprofit agriculture organization to offer health benefits to its members.
In a letter to the Rhode Island General Assembly, the Cystic Fibrosis Foundation expressed its support of 8041, which if passed, would ban all state-regulated payers from including co-pay accumulator programs in their health insurance plans.
In a letter to Colorado legislators, the Cystic Fibrosis Foundation expressed its support for SB 24-203 which, if passed, would require that the state’s Prescription Drug Affordability Board consider orphan drug status and, if the drug is an orphan drug, patient input when selecting drugs for affordability review.
The Cystic Fibrosis Foundation joined the Partnership for Protecting Coverage in a letter to the U.S. Department of Health and Human Services supporting CHIP eligibility expansion in Florida but opposing a proposal that would disenroll families who fail to pay premiums.
In a letter to Mississippi legislators, the Cystic Fibrosis Foundation expressed support for HB 1725 which, if passed, would expand eligibility for Medicaid. The letter also urged legislators to ensure that the bill expands eligibility to adults with incomes up to 138% of the federal poverty line.
In a letter to the Vermont Senate, the Cystic Fibrosis Foundation expressed its support for HB 233, which, if passed, would ban co-pay accumulator programs in the state and require covered benefits to be considered essential health benefits.